Fecal calprotectin in clinical practice: a noninvasive screening tool for patients with chronic diarrhea

Antonio Craxi, Ada Maria Florena, Anna Licata, Calogero Camma', Vincenza Calvaruso, Calogero Cammà, Antonio Craxì, Maria Cappello, Sergio Peralta, Vincenza Calvaruso, Giuseppe Butera, Claudia Randazzo, Anna Licata

Risultato della ricerca: Article

22 Citazioni (Scopus)

Abstract

Background: Surrogate markers of colorectal inflammation are increasingly being recognized as important in differentiating organic from functional intestinal disorders. Fecal calprotectin (FC) can be easily measured in the stool, being released by leukocytes in inflammatory conditions. Aim: We evaluated FC as an index of inflammation in consecutive outpatients referred for colonoscopy for chronic, nonbloody diarrhea. Methods: Stool specimens of 346 outpatients with chronic, nonbloody diarrhea, referred for colonoscopy, were measured for FC levels. The proportion of patients correctly diagnosed with the test and the relationship with endoscopic and histologic findings were measured. Results: Abnormal endoscopic findings were detected in 104 patients (30.1%). Histologic findings included 142 patients (41.0%) with inflammation and 204 (59.0%) without inflammation. Fecal excretion of calprotectin significantly correlated with the finding of inflammation at endoscopy and histology (P<0.0001). When 150 mcg/g of stool was used as the upper reference limit, FC showed 75.4% sensitivity and 88.3% specificity, with 81.7% positive and 83.7% negative predictive values for histologic inflammation. Conclusions: In outpatients referred for colonoscopy a measurement of FC is accurate to identify those with histologic inflammation. Assay of FC may be a reliable and noninvasive screening tool to identify inflammatory causes of chronic, nonbloody diarrhea
Lingua originaleEnglish
pagine (da-a)504-508
Numero di pagine5
RivistaJournal of Clinical Gastroenterology
Volume46
Stato di pubblicazionePublished - 2012

Fingerprint

Leukocyte L1 Antigen Complex
Diarrhea
Inflammation
Colonoscopy
Outpatients
Endoscopy
Histology
Leukocytes
Biomarkers
Sensitivity and Specificity

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cita questo

Fecal calprotectin in clinical practice: a noninvasive screening tool for patients with chronic diarrhea. / Craxi, Antonio; Florena, Ada Maria; Licata, Anna; Camma', Calogero; Calvaruso, Vincenza; Cammà, Calogero; Craxì, Antonio; Cappello, Maria; Peralta, Sergio; Calvaruso, Vincenza; Butera, Giuseppe; Randazzo, Claudia; Licata, Anna.

In: Journal of Clinical Gastroenterology, Vol. 46, 2012, pag. 504-508.

Risultato della ricerca: Article

Craxi, A, Florena, AM, Licata, A, Camma', C, Calvaruso, V, Cammà, C, Craxì, A, Cappello, M, Peralta, S, Calvaruso, V, Butera, G, Randazzo, C & Licata, A 2012, 'Fecal calprotectin in clinical practice: a noninvasive screening tool for patients with chronic diarrhea', Journal of Clinical Gastroenterology, vol. 46, pagg. 504-508.
Craxi, Antonio ; Florena, Ada Maria ; Licata, Anna ; Camma', Calogero ; Calvaruso, Vincenza ; Cammà, Calogero ; Craxì, Antonio ; Cappello, Maria ; Peralta, Sergio ; Calvaruso, Vincenza ; Butera, Giuseppe ; Randazzo, Claudia ; Licata, Anna. / Fecal calprotectin in clinical practice: a noninvasive screening tool for patients with chronic diarrhea. In: Journal of Clinical Gastroenterology. 2012 ; Vol. 46. pagg. 504-508.
@article{340ae6c4c7f34e898879390777f030dc,
title = "Fecal calprotectin in clinical practice: a noninvasive screening tool for patients with chronic diarrhea",
abstract = "Background: Surrogate markers of colorectal inflammation are increasingly being recognized as important in differentiating organic from functional intestinal disorders. Fecal calprotectin (FC) can be easily measured in the stool, being released by leukocytes in inflammatory conditions. Aim: We evaluated FC as an index of inflammation in consecutive outpatients referred for colonoscopy for chronic, nonbloody diarrhea. Methods: Stool specimens of 346 outpatients with chronic, nonbloody diarrhea, referred for colonoscopy, were measured for FC levels. The proportion of patients correctly diagnosed with the test and the relationship with endoscopic and histologic findings were measured. Results: Abnormal endoscopic findings were detected in 104 patients (30.1{\%}). Histologic findings included 142 patients (41.0{\%}) with inflammation and 204 (59.0{\%}) without inflammation. Fecal excretion of calprotectin significantly correlated with the finding of inflammation at endoscopy and histology (P<0.0001). When 150 mcg/g of stool was used as the upper reference limit, FC showed 75.4{\%} sensitivity and 88.3{\%} specificity, with 81.7{\%} positive and 83.7{\%} negative predictive values for histologic inflammation. Conclusions: In outpatients referred for colonoscopy a measurement of FC is accurate to identify those with histologic inflammation. Assay of FC may be a reliable and noninvasive screening tool to identify inflammatory causes of chronic, nonbloody diarrhea",
author = "Antonio Craxi and Florena, {Ada Maria} and Anna Licata and Calogero Camma' and Vincenza Calvaruso and Calogero Camm{\`a} and Antonio Crax{\`i} and Maria Cappello and Sergio Peralta and Vincenza Calvaruso and Giuseppe Butera and Claudia Randazzo and Anna Licata",
year = "2012",
language = "English",
volume = "46",
pages = "504--508",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Fecal calprotectin in clinical practice: a noninvasive screening tool for patients with chronic diarrhea

AU - Craxi, Antonio

AU - Florena, Ada Maria

AU - Licata, Anna

AU - Camma', Calogero

AU - Calvaruso, Vincenza

AU - Cammà, Calogero

AU - Craxì, Antonio

AU - Cappello, Maria

AU - Peralta, Sergio

AU - Calvaruso, Vincenza

AU - Butera, Giuseppe

AU - Randazzo, Claudia

AU - Licata, Anna

PY - 2012

Y1 - 2012

N2 - Background: Surrogate markers of colorectal inflammation are increasingly being recognized as important in differentiating organic from functional intestinal disorders. Fecal calprotectin (FC) can be easily measured in the stool, being released by leukocytes in inflammatory conditions. Aim: We evaluated FC as an index of inflammation in consecutive outpatients referred for colonoscopy for chronic, nonbloody diarrhea. Methods: Stool specimens of 346 outpatients with chronic, nonbloody diarrhea, referred for colonoscopy, were measured for FC levels. The proportion of patients correctly diagnosed with the test and the relationship with endoscopic and histologic findings were measured. Results: Abnormal endoscopic findings were detected in 104 patients (30.1%). Histologic findings included 142 patients (41.0%) with inflammation and 204 (59.0%) without inflammation. Fecal excretion of calprotectin significantly correlated with the finding of inflammation at endoscopy and histology (P<0.0001). When 150 mcg/g of stool was used as the upper reference limit, FC showed 75.4% sensitivity and 88.3% specificity, with 81.7% positive and 83.7% negative predictive values for histologic inflammation. Conclusions: In outpatients referred for colonoscopy a measurement of FC is accurate to identify those with histologic inflammation. Assay of FC may be a reliable and noninvasive screening tool to identify inflammatory causes of chronic, nonbloody diarrhea

AB - Background: Surrogate markers of colorectal inflammation are increasingly being recognized as important in differentiating organic from functional intestinal disorders. Fecal calprotectin (FC) can be easily measured in the stool, being released by leukocytes in inflammatory conditions. Aim: We evaluated FC as an index of inflammation in consecutive outpatients referred for colonoscopy for chronic, nonbloody diarrhea. Methods: Stool specimens of 346 outpatients with chronic, nonbloody diarrhea, referred for colonoscopy, were measured for FC levels. The proportion of patients correctly diagnosed with the test and the relationship with endoscopic and histologic findings were measured. Results: Abnormal endoscopic findings were detected in 104 patients (30.1%). Histologic findings included 142 patients (41.0%) with inflammation and 204 (59.0%) without inflammation. Fecal excretion of calprotectin significantly correlated with the finding of inflammation at endoscopy and histology (P<0.0001). When 150 mcg/g of stool was used as the upper reference limit, FC showed 75.4% sensitivity and 88.3% specificity, with 81.7% positive and 83.7% negative predictive values for histologic inflammation. Conclusions: In outpatients referred for colonoscopy a measurement of FC is accurate to identify those with histologic inflammation. Assay of FC may be a reliable and noninvasive screening tool to identify inflammatory causes of chronic, nonbloody diarrhea

UR - http://hdl.handle.net/10447/73461

M3 - Article

VL - 46

SP - 504

EP - 508

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

ER -